- Home
- RDZN vs MRSN Comparison
RDZN vs MRSN Comparison
Compare RDZN & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDZN
- MRSN
- Stock Information
- Founded
- RDZN 2015
- MRSN 2001
- Country
- RDZN United States
- MRSN United States
- Employees
- RDZN N/A
- MRSN N/A
- Industry
- RDZN Blank Checks
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- RDZN Finance
- MRSN Health Care
- Exchange
- RDZN Nasdaq
- MRSN Nasdaq
- Market Cap
- RDZN 86.1M
- MRSN 71.9M
- IPO Year
- RDZN N/A
- MRSN 2017
- Fundamental
- Price
- RDZN $1.16
- MRSN $0.31
- Analyst Decision
- RDZN Strong Buy
- MRSN Buy
- Analyst Count
- RDZN 2
- MRSN 3
- Target Price
- RDZN $5.00
- MRSN $4.00
- AVG Volume (30 Days)
- RDZN 178.0K
- MRSN 3.0M
- Earning Date
- RDZN 02-12-2025
- MRSN 03-03-2025
- Dividend Yield
- RDZN N/A
- MRSN N/A
- EPS Growth
- RDZN N/A
- MRSN N/A
- EPS
- RDZN N/A
- MRSN N/A
- Revenue
- RDZN $42,893,256.00
- MRSN $40,497,000.00
- Revenue This Year
- RDZN $4.52
- MRSN N/A
- Revenue Next Year
- RDZN $53.72
- MRSN N/A
- P/E Ratio
- RDZN N/A
- MRSN N/A
- Revenue Growth
- RDZN 2.79
- MRSN 9.88
- 52 Week Low
- RDZN $0.71
- MRSN $0.31
- 52 Week High
- RDZN $6.67
- MRSN $4.64
- Technical
- Relative Strength Index (RSI)
- RDZN 51.69
- MRSN 26.66
- Support Level
- RDZN $0.96
- MRSN $0.41
- Resistance Level
- RDZN $1.38
- MRSN $0.37
- Average True Range (ATR)
- RDZN 0.13
- MRSN 0.04
- MACD
- RDZN 0.03
- MRSN -0.00
- Stochastic Oscillator
- RDZN 47.62
- MRSN 0.00
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform global auto insurance powered by advanced AI. Its clients comprise major insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.